PDF(Pubmed)
Abstract：
Purpose: This study aimed to determine the efficacy of the dexamethasone (DEX) intravitreal implant for the regression of macular edema and the improvement of best-corrected visual acuity (BCVA) after the removal of idiopathic epiretinal membrane (ERM). Methods: This prospective randomized controlled trial recruited 81 patients with idiopathic ERM. These patients all underwent 25-gauge pars plana vitrectomy combined with ERM and internal limiting membrane peeling surgery. Among them, 41 eyes in the DEX group received additional DEX implants and 40 in the non-DEX group did not. Outcomes including central retinal thickness (CRT), BCVA, and intraocular pressure were measured 1 and 3 months after surgery. Results: The DEX group had thinner CRTs compared to the non-DEX group at 1 month postoperatively (p <0.05), but did not differ significantly at the 1-week and 3-month follow-up visits (p = 0.109 and p = 0.417, respectively). There were no statistical differences with respect to BCVA (p = 0.499, 0.309, 0.246, and 0.517, respectively) and intraocular pressure (p = 0.556, 0.639, 0.741, and 0.517, respectively) between the two groups at each point of follow-up visits. Conclusion: DEX accelerated the reduction of CRT at 1 month after surgery. However, no evidence of further anatomical (CRT) or functional (BCVA) benefits using DEX was observed at 3 months. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT05416827.
摘要：
目的：本研究旨在确定地塞米松（DEX）玻璃体内植入物对去除特发性视网膜前膜（ERM）后黄斑水肿消退和最佳矫正视力（BCVA）改善的疗效。方法：这项前瞻性随机对照试验招募了81例特发性ERM患者。这些患者均接受了25号平面玻璃体切除术联合ERM和内界膜剥离手术。其中,DEX组41只眼接受了额外的DEX植入物，非DEX组40只眼未接受。结果包括中央视网膜厚度（CRT），BCVA,术后1个月和3个月测量眼压。结果:术后1个月DEX组比非DEX组有更薄的CRT(p<0.05),但在1周和3个月的随访中没有显着差异（分别为p=0.109和p=0.417）。两组之间在BCVA（分别为p=0.499、0.309、0.246和0.517）和眼压（分别为p=0.556、0.639、0.741和0.517）方面没有统计学差异。随访。结论：DEX在术后1个月加速了CRT的减少。然而,在3个月时未观察到使用DEX的进一步解剖学(CRT)或功能性(BCVA)获益的证据.临床试验注册：https://clinicaltrials.gov/,标识符NCT05416827。
